Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Expression of Glypican 3 is an Independent Prognostic Biomarker in Primary Gastro-Esophageal Adenocarcinoma and Corresponding Serum Exosomes

Title: Expression of Glypican 3 is an Independent Prognostic Biomarker in Primary Gastro-Esophageal Adenocarcinoma and Corresponding Serum Exosomes
Authors: Mohammad Rahbari; Mathieu Pecqueux; Daniela Aust; Holger Stephan; Oliver Tiebel; Antonios Chatzigeorgiou; Torsten Tonn; Franziska Baenke; Venkatesh Rao; Nicole Ziegler; Helena Greif; Kuailu Lin; Juergen Weitz; Nuh Nabi Rahbari; Christoph Kahlert
Source: Journal of Clinical Medicine, Vol 8, Iss 5, p 696 (2019)
Publisher Information: MDPI AG
Publication Year: 2019
Collection: Directory of Open Access Journals: DOAJ Articles
Subject Terms: tumor antigen; immune profile; lymph node; antibody secreting cell; biomarker; microarray; breast cancer; immunotherapy; Medicine
Description: Exosomes are nano-sized membranous vesicles of endosomal origin that carry nucleic acids, lipids and proteins. The cargo of exosomes is cell origin specific and the release of these exosomes and uptake by an acceptor cell is seen as a vital element of cell-cell communication. Here, we sought to investigate the diagnostic and prognostic value of the expression of glypican 3 ( GPC3 ) on primary gastro-esophageal adenocarcinoma (GEA) tissue ( tGPC3 ) and corresponding serum exosomes ( eGPC3 ). Circulating exosomes were extracted from serum samples of 49 patients with GEA and 56 controls. Extracted exosomes were subjected to flow cytometry for the expression of eGPC3 and GPC3 expression on primary GEA tissue samples was determined by immunohistochemistry and correlated to clinicopathological parameters. We found decreased eGPC3 levels in GEA patients compared to healthy controls ( p < 0.0001) and high tGPC3 expression. This was significantly associated with poor overall survival (high vs. low eGPC3 : 87.40 vs. 60.93 months, p = 0.041, high vs. low tGPC3 : 58.03 vs. 84.70 months, p = 0.044). Cox regressional analysis confirmed tGPC3 as an independent prognostic biomarker for GEA ( p = 0.02) and tGPC3 expression was validated in two independent cohorts. Our findings demonstrate that eGPC3 and tGPC3 can be used as potential diagnostic and prognostic biomarkers for GEA.
Document Type: article in journal/newspaper
Language: English
Relation: https://www.mdpi.com/2077-0383/8/5/696; https://doaj.org/toc/2077-0383; https://doaj.org/article/277bb36b20ef427cb875552b6124bf9b
DOI: 10.3390/jcm8050696
Availability: https://doi.org/10.3390/jcm8050696; https://doaj.org/article/277bb36b20ef427cb875552b6124bf9b
Accession Number: edsbas.89768231
Database: BASE